Travere Therapeutics (TVTX) Deferred Taxes (2014 - 2017)

Travere Therapeutics has reported Deferred Taxes for 4 years, with the latest figure at $1.4 million in Q4 2017.

• For the quarter ending Q4 2017, Deferred Taxes rose 111.88% year-over-year to $1.4 million; the trailing twelve-month figure through Sep 2018 stood at $1.4 million (up 107.12% YoY), and the FY2017 full-year result was -$6.4 million, up 71.65% from the prior year.
• Deferred Taxes for Q4 2017 stood at $1.4 million, up from -$2.4 million in the prior quarter.
• The five-year high for Deferred Taxes was $28.2 million in Q3 2015, with the low at -$40.0 million in Q1 2015.
• Historically, Deferred Taxes has averaged -$3.9 million across 4 years, with a median of -$2.9 million in 2014.
• The largest YoY upside for Deferred Taxes was 111.88% in 2017 against a maximum downside of 285.78% in 2017.
• Travere Therapeutics' Deferred Taxes stood at -$2.5 million in 2014, then plunged by 53.74% to -$3.8 million in 2015, then plunged by 208.36% to -$11.7 million in 2016, then soared by 111.88% to $1.4 million in 2017.
• The last three Deferred Taxes figures came in at $1.4 million (Q4 2017), -$2.4 million (Q3 2017), and -$3.4 million (Q2 2017), per Business Quant data.